Companies › NextPoint Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NPX372 B7-H7:CD3 bispecific antibody | PDCD7, CD3E | Phase 1 | Metastatic Malignant Neoplasm | Apr 2027 |
| NPX887 B7-H7/HHLA2 antagonistic monoclonal antibody | HHLA2 | Phase 1 | Metastatic Malignant Neoplasm | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07563829 | NPX372 | Phase 1 | Metastatic Malignant Neoplasm | Oncology | Apr 2027 |
| NCT06240728 | NPX887 | Phase 1 | Metastatic Malignant Neoplasm | Oncology | Aug 2027 |
Johnson & Johnson (Janssen) Regeneron Pharmaceuticals Amgen Roche AstraZeneca Tiziana Life Sciences Sanofi Shine-On Biomedical Pfizer Cullinan Therapeutics
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.